Business
Satellos Reports First Quarter 2026 Financial Results and Highlights Company Progress
Eleven clinical trial sites in BASECAMP currently active; remaining planned sites to be activated throughout Q2 2026BASECAMP remains on track to complete enrollment in Q3 2026The Company has initiated the TRAILHEAD study in the U.S. in adults aged 16-25 years.Current cash available of $69.9M (Cdn $97.5M) provides runway through 2027 TORONTO, May 15, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company de
About this update from Satellos Bioscience Inc
[{"type":"image","alt":"Satellos Bioscience Inc.","displaySize":"","headline":null,"caption":"Satellos Bioscience Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":169,"url":"https://media.zenfs.com/en/globenewswire.com/bb5c33a8b09d2459f701e059afed2391"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_k6qvkR9xj0jRrv7B95GQA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIzNw--/https://media.zenfs.com/en/globenewswire.com/bb5c33a8b09d2459f701e059afed2391","width":300,"height":169},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/_k6qvkR9xj0jRrv7B95GQA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIzNw--/https://media.zenfs.com/en/globenewswire.com/bb5c33a8b09d2459f701e059afed2391","width":300,"height":169}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Eleven clinical trial sites in BASECAMP currently active; remaining planned sites to be activated throughout Q2 2026","length":116,"tagName":"p"}]},{"val":[{"type":"text","content":"BASECAMP remains on track to complete enrollment in Q3 2026","length":59,"tagName":"p"}]},{"val":[{"type":"text","content":"The Company has initiated the TRAILHEAD study in the U.S. in adults aged 16-25 years.","length":85,"tagName":"p"}]},{"val":[{"type":"text","content":"Current cash available of $69.9M (Cdn $97.5M) provides runway through 2027","length":74,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":334,"olType":false},{"type":"text","content":"TORONTO, May 15, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced financial results and corporate highlights for the first quarter ended March 31, 2026.","length":340,"tagName":"p"},{"type":"text","content":"“The first quarter of 2026 was a productive time for Satellos. We raised $57M, providing runway to meet all planned milestones through the end of 2027, uplisted to Nasdaq, and advanced the Phase 2 TRAILHEAD and BASECAMP studies,” said Frank Gleeson, MBA, Chief Executive Officer of Satellos. “We are excited by the progress we are making with BASECAMP enrollment and dosing across 11 active clinical sites to date. We expect the additional sites intended to complete BASECAMP to be activated in Q2. We remain on track to complete BAS...